SN Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.…
Industry Peers
Medical DevicesKey Statistics
About Smith & Nephew (LON: SN)
›
Smith & Nephew (LON: SN) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 17,000 employees.
The shares were at 1135.00 GBp on 19 November 2026, down 11.4% over 52 weeks. Its 52-week range is 980.40 GBp to 1396.50 GBp: the price is 18.7% below the high and 15.8% above the low.
At a market capitalisation of 9.49B GBP, it trades at 20.6 times trailing earnings and 13.1 times forward earnings. The median trailing P/E of its 18 largest Medical Devices peers is 26.3, a discount of 22% for SN. It pays a dividend yielding 2.56% (it pays out 53% of its earnings), against a median of 1.97% among the dividend payers in that peer group.
Smith & Nephew reports return on equity of 11.8%, an operating margin of 14.2% and revenue up 4.6% year over year.
Its debt exceeds its cash by 3.03B USD, a debt-to-equity ratio of 0.63. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 17 analysts cover the stock, with an average rating of Hold; their mean price target of 1256.00 GBp is 10.7% above the current price. The next earnings report is expected on 1 March 2027.